Sovenyr Subscribe

Signal2026-07-21

MarketWatch RSS

Novo Nordisk sues Eli Lilly over ads as GLP-1 market hits ‘inflection point’

Open primary source Read on Substack

Powered by Sovenyr — cross-source signal intelligence. Figures are collected data as-dated, not investment advice.